D STIMULATED VS UNSTIMULATED 10W UP, FLETCHER PBMC BCG 10W INFANT PPD STIMULATED VS UNSTIMULATED 10W UP

```
MATSUMIYA PBMC MODIFIED VACCINIA ANKARA VACCINE AGE 18 55YO 2DY UP, MATSUMIYA PBMC MODIFIED VACCINIA ANKARA VACCINE AGE 18 55YO 2DY UP
   FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_UP, FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_UP
  HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP, HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
  ERWIN_COHEN_BLOOD_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_UP, ERWIN_COHEN_BLOOD_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_UP
   SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_UP, SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_UP
  ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_UP, ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_UP
 NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_ATIV_UP, NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_ATIV_UP
 PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_TOP_30_DEG_UP, PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_TOP_30_DEG_UP
 FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_UP, FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_UP
 MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP, MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP, MATSUMIYA_PBMC_MODIFIED_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP, MATSUMIYA_PBMC_MODIFIED_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP, MATSUMIYA_PBMC_MODIFIED_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP, MATSUMIYA_PBMC_MODIFIED_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP, MATSUMIYA_PBMC_WITRO_WITH_MVA85A_FINATED_VS_CONTROL_TREATED_IN_VITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WITRO_WIT
   QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_7DY_UP, QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_7DY_UP
   LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_UP, LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_UP
 _{I} ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NAIVE_NOT_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP, ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NAIVE_NOT_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP
   HARALAMBIEVA_PBMC_M_M_R_II_AGE_13_16YO_STIMULATED_VS_UNSTIMULATED_3_TO_7YR_POST_TOP_DEG_UP, HARALAMBIEVA_PBMC_M_M_R_II_AGE_13_16YO_STIMULATED_VS_UNSTIMULATED_3_TO_7YR_POST_TOP_DEG_UP
   LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_DN, LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_DN
   NAKAYA_PBMC_IMUVAC_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0DY_PREIMM_TIV_UP, NAKAYA_PBMC_IMUVAC_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0DY_PREIMM_TIV_UP
   HOWARD T CELL INACT MONOV INFLUENZA A INDONESIA 05 2005 H5N1 AGE 18 49YO 1DY UP, HOWARD T CELL INACT MONOV INFLUENZA A INDONESIA 05 2005 H5N1 AGE 18 49YO 1DY UP
   SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_7DY_DN, SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_7DY_DN
  RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_TOP_FUNCTIONAL_NETWORK_UP, RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_TOP_FUNCTIONAL_NETWORK_UP
LI PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_NEGATIVE, LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_NEGATIVE
✓ LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_NEGATIVE, LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_NEGATIVE
 - PATEL SKIN OF BODY ZOSTAVAX AGE 70 93YO VZV CHALLENGED POST VACCINATION VS UNCHALLENGED 72HR TOP 30 DEG UP, PATEL SKIN OF BODY ZOSTAVAX AGE 70 93YO VZV CHALLENGED POST VACCINATION VS UNCHALLENGED 72HR TOP 30 DEG
  HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_DN, HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_DN
   HOEK MYELOID DENDRITIC CELL 2011 2012 TIV ADULT 7DY UP, HOEK MYELOID DENDRITIC CELL 2011 2012 TIV ADULT 7DY UP
  SCHERER_PBMC_YF_VAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP, SCHERER_PBMC_YF_VAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP
   SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP, SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP
    HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR UP, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT AND TREATMENT A
  'VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_UP, VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_UP
   HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP, HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP
   MATSUMIYA_BLOOD_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_11
   HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED LOW ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M R TREATMENT 7YR DN, TREAT
   HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_DN, HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_DN
  HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP, HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP
  OVSYANNIKOVA PBMC FLUARIX AGE 50 74YO COMMON WITH BOTH HAI AND VNA 28DY VS 3DY USED IN HAI AND VNA RESPONSE MODELS UP, OVSYANNIKOVA PBMC FLUARIX AGE 50 74YO COMMON WITH BOTH HAI AND VNA 28DY VS 3DY USED IN HAI
 COLE_BLOOD_FLUZONE_FLUARIX_AGE_03_17YO_7DY_DN, COLE_BLOOD_FLUZONE_FLUARIX_AGE_03_17YO_7DY_DN
  HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT TO TREA
   RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_0W_14W_METALLOTHIONEIN_SUBSET_UP, RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_0W_14W_METALLOTHIONEIN_SUBSET_UP
  WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_4_POST_BOOSTER_VACC_1DY_POSITIVE, WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_4
  FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_DN, FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_DN
   NAKAYA PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_DN, NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_DN
  CAO_BLOOD_FLUMIST_AGE_05_14YO_CORRELATED_WITH_H3N2_VN_TITER_7DY_POSITIVE, CAO_BLOOD_FLUMIST_AGE_05_14YO_CORRELATED_WITH_H3N2_VN_TITER_7DY_POSITIVE
   RECHTIEN_PBMC_RVSV_ZEBOV_AGE_18_55YO_1DY_UP, RECHTIEN_PBMC_RVSV_ZEBOV_AGE_18_55YO_1DY_UP
```